{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:36:05Z","timestamp":1792794965868,"version":"4.5.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"SI2","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Chinese Pharmaceutical Association Hospital Pharmacy Committee","award":["CPA-Z05-ZC-2021\u2013003"],"award-info":[{"award-number":["CPA-Z05-ZC-2021\u2013003"]}],"id":[{"id":"https:\/\/ror.org\/023q20n38","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Mycophenolic acid (MPA) is recommended for lupus nephritis (LN) treatment, but with large inter-individual variability in pharmacokinetics (PK). The aim of this study is to reveal the relationship between MPA exposure and disease response and adverse drug reactions in pediatric LN patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This was a population-based observational cohort study. A total of 86 pediatric LN patients treated with mycophenolate mofetil (MMF) for induction therapy were enrolled. The area-under the concentration-time curve (AUC) was calculated using MPA concentrations according to a limited sampling strategy. Receiver operating characteristic analysis was performed to assess the MPA-AUC threshold values. The cumulative incidence of renal remission and inactive systemic lupus erythematosus (SLE) over time was evaluated by Kaplan\u2013Meier\u2019s analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>MPA-AUC was identified as an independent factor associated with renal remission and lupus activity at 6 and 12\u2009months after MMF treatment, and the improved renal remission rates were correlated with higher MPA-AUC, with thresholds of 29.81 and 30.63\u2009\u03bcg\u00b7h\u00b7mL\u22121 at 6\u00a0months and 12\u2009months, respectively. Furthermore, the thresholds for maintaining the hypoactive state of LN were 30.96 and 31.19\u2009\u03bcg\u00b7h\u00b7mL\u22121at 6\u2009months and 12\u2009months, respectively. Patients reaching target thresholds for MPA-AUC achieved renal response or stable disease earlier. In addition, the MPA-AUC threshold for decreasing MMF-related adverse reactions was 50.80\u2009\u03bcg\u00b7h\u00b7mL\u22121.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The initial and long-term treatments of pediatric LN patients with MMF should be individualized according to the MPA-AUC, and the recommended MPA exposure is 31.19\u201350.80\u2009\u03bcg\u00b7h\u00b7mL\u22121.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae264","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T07:58:40Z","timestamp":1715241520000},"page":"SI180-SI187","source":"Crossref","is-referenced-by-count":11,"title":["Optimal exposure of mycophenolic acid for induction therapy of childhood lupus nephritis patients: an observational cohort study"],"prefix":"10.1093","volume":"63","author":[{"given":"Lu","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital, Sun Yat-sen University , Guangzhou, China"},{"name":"Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-sen University , Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology and Rheumatology, The First Affiliated Hospital, Sun Yat-sen University , Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology and Rheumatology, The First Affiliated Hospital, Sun Yat-sen University , Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology and Rheumatology, The First Affiliated Hospital, Sun Yat-sen University , Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zheng","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Michigan , Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejing","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital, Sun Yat-sen University , Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology and Rheumatology, The First Affiliated Hospital, Sun Yat-sen University , Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9324-5490","authenticated-orcid":false,"given":"Pan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital, Sun Yat-sen University , Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"2024090907515639200_keae264-B1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.pcl.2012.03.007","article-title":"Systemic lupus erythematosus in children and adolescents","volume":"59","author":"Levy","year":"2012","journal-title":"Pediatr Clin North Am"},{"key":"2024090907515639200_keae264-B2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5527\/wjn.v3.i2.16","article-title":"Pediatric lupus nephritis: management update","volume":"3","author":"Sinha","year":"2014","journal-title":"World J Nephrol"},{"key":"2024090907515639200_keae264-B3","first-page":"351","article-title":"Paediatric-onset systemic lupus erythematosus. Best practice & research","volume":"27","author":"Malattia","year":"2013","journal-title":"Clin Rheumatol"},{"key":"2024090907515639200_keae264-B4","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1177\/0961203316660625","article-title":"Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa","volume":"26","author":"Lewandowski","year":"2017","journal-title":"Lupus"},{"key":"2024090907515639200_keae264-B5","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.rdc.2013.05.001","article-title":"Biomarkers and updates on pediatrics lupus nephritis","volume":"39","author":"Bennett","year":"2013","journal-title":"Rheum Dis Clin North Am"},{"key":"2024090907515639200_keae264-B6","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.semarthrit.2015.11.013","article-title":"Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts","volume":"45","author":"J\u00f6nsen","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2024090907515639200_keae264-B7","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1007\/s00296-015-3344-8","article-title":"Direct medical costs and their predictors in South Korean patients with systemic lupus erythematosus","volume":"35","author":"Park","year":"2015","journal-title":"Rheumatol Int"},{"key":"2024090907515639200_keae264-B8","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/acr.20410","article-title":"Cost-of-illness studies in systemic lupus erythematosus: a systematic review","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2024090907515639200_keae264-B9","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00296-016-3551-y","article-title":"Medical costs incurred by organ damage caused by active disease, comorbidities and side effect of treatments in systemic lupus erythematosus patients: a Taiwan nationwide population-based study","volume":"36","author":"Chiu","year":"2016","journal-title":"Rheumatol Int"},{"key":"2024090907515639200_keae264-B10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40744-021-00368-y","article-title":"The economic burden of lupus nephritis: a systematic literature review","volume":"9","author":"Thompson","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2024090907515639200_keae264-B11","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00467-016-3437-y","article-title":"Effect of mycophenolic acid in experimental, nontransplant glomerular diseases: new mechanisms beyond immune cells","volume":"32","author":"Hackl","year":"2017","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"key":"2024090907515639200_keae264-B12","first-page":"e00294","article-title":"Inhibition of tRNA gene transcription by the immunosuppressant mycophenolic acid","volume":"40","author":"Jurkiewicz","year":"2019","journal-title":"Mol Cell Biol"},{"key":"2024090907515639200_keae264-B13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1567-5769(02)00210-2","article-title":"Mycophenolic acid inhibits inosine 5'-monophosphate dehydrogenase and suppresses immunoglobulin and cytokine production of B cells","volume":"3","author":"Jonsson","year":"2003","journal-title":"Int Immunopharmacol"},{"key":"2024090907515639200_keae264-B14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1600-6143.2010.03413.x","article-title":"Mycophenolic acid-mediated suppression of human CD4+ T cells: more than mere guanine nucleotide deprivation","volume":"11","author":"He","year":"2011","journal-title":"Am J Transplant"},{"key":"2024090907515639200_keae264-B15","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.4049\/jimmunol.1003319","article-title":"Mycophenolic acid differentially impacts B cell function depending on the stage of differentiation","volume":"187","author":"Karnell","year":"2011","journal-title":"J Immunol (Baltimore, MD.: 1950)"},{"key":"2024090907515639200_keae264-B16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrneph.2015.33","article-title":"Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis","volume":"11","author":"Mohan","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"2024090907515639200_keae264-B17","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/0961203313485490","article-title":"Pediatric lupus nephritis: more options, more chances?","volume":"22","author":"Vachvanichsanong","year":"2013","journal-title":"Lupus"},{"key":"2024090907515639200_keae264-B18","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1136\/annrheumdis-2017-211898","article-title":"European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative","volume":"76","author":"Groot","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024090907515639200_keae264-B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rbr.2014.09.008","article-title":"[Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis]","volume":"55","author":"Klumb","year":"2015","journal-title":"Rev Brasil Reumatol"},{"key":"2024090907515639200_keae264-B20","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1136\/annrheumdis-2016-210960","article-title":"European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative","volume":"76","author":"Groot","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024090907515639200_keae264-B21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/nep.12136","article-title":"Overview of lupus nephritis management guidelines and perspective from Asia","volume":"19","author":"Mok","year":"2014","journal-title":"Nephrology (Carlton, Vic.)"},{"key":"2024090907515639200_keae264-B22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/jcph.1565","article-title":"Mycophenolic acid and its pharmacokinetic drug-drug interactions in humans: review of the evidence and clinical implications","volume":"60","author":"Benjanuwattra","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"2024090907515639200_keae264-B23","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/art.27495","article-title":"Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil","volume":"62","author":"Zahr","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2024090907515639200_keae264-B24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/FTD.0000000000000031","article-title":"Pharmacokinetics of concentration-controlled mycophenolate mofetil in proliferative lupus nephritis: an observational cohort study","volume":"36","author":"Alexander","year":"2014","journal-title":"Ther Drug Monitor"},{"key":"2024090907515639200_keae264-B25","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2215\/CJN.07111009","article-title":"Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation","volume":"5","author":"Kuypers","year":"2010","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"2024090907515639200_keae264-B26","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/FTD.0b013e31818b8244","article-title":"Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation","volume":"30","author":"Mino","year":"2008","journal-title":"Ther Drug Monitor"},{"key":"2024090907515639200_keae264-B27","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s10157-018-1590-2","article-title":"Investigation on the benefits of mycophenolate mofetil and therapeutic drug monitoring in the treatment of Japanese patients with lupus nephritis","volume":"22","author":"Katsuno","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"2024090907515639200_keae264-B28","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/bcp.12678","article-title":"Exposure-effect relationship of mycophenolic acid and prednisolone in adult patients with lupus nephritis","volume":"80","author":"Abd Rahman","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"2024090907515639200_keae264-B29","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/14397595.2019.1623435","article-title":"High plasma mycophenolate acid concentration in the early phase of induction therapy predicts good renal outcome in lupus nephritis","volume":"30","author":"Kiyokawa","year":"2020","journal-title":"Modern Rheumatol"},{"key":"2024090907515639200_keae264-B30","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10067-014-2786-9","article-title":"Optimizing the dose of mycophenolate mofetil for the maintenance treatment of lupus nephritis by therapeutic drug monitoring","volume":"34","author":"Zabotti","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2024090907515639200_keae264-B31","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00467-020-04733-x","article-title":"Mycophenolic acid area under the concentration-time curve is associated with therapeutic response in childhood-onset lupus nephritis","volume":"36","author":"Godron-Dubrasquet","year":"2021","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"key":"2024090907515639200_keae264-B32","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024090907515639200_keae264-B33","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"2024090907515639200_keae264-B34","first-page":"1729","article-title":"Development and application of HPLC method in simultaneous determination of mycophenolic acid and its 7-O-glucuronide metabolite in human plasma","author":"Huang","year":"2011"},{"key":"2024090907515639200_keae264-B35","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/aps.2015.7","article-title":"Associations of UDP-glucuronosyltransferases polymorphisms with mycophenolate mofetil pharmacokinetics in Chinese renal transplant patients","volume":"36","author":"Xie","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"2024090907515639200_keae264-B36","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1053\/j.ajkd.2012.08.041","article-title":"Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials","volume":"61","author":"Henderson","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2024090907515639200_keae264-B37","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/rheumatology\/kep120","article-title":"Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression","volume":"48","author":"Mak","year":"2009","journal-title":"Rheumatology (Oxford, England)"},{"key":"2024090907515639200_keae264-B38","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"New Engl J Med"},{"key":"2024090907515639200_keae264-B39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/IJWH.S28034","article-title":"Understanding lupus nephritis: diagnosis, management, and treatment options","volume":"4","author":"Mok","year":"2012","journal-title":"Int J Women's Health"},{"key":"2024090907515639200_keae264-B40","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1472-8206.2008.00644.x","article-title":"Tacrolimus pharmacokinetic drug interactions: effect of prednisone, mycophenolic acid or sirolimus","volume":"23","author":"Park","year":"2009","journal-title":"Fundam Clin Pharmacol"},{"key":"2024090907515639200_keae264-B41","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/ndt\/gfy284","article-title":"Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis","volume":"35","author":"Yap","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2024090907515639200_keae264-B42","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bcp.12392","article-title":"Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring","volume":"78","author":"Woillard","year":"2014","journal-title":"Br J Clin Pharmacol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae264\/57909299\/keae264.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/SI2\/SI180\/59038612\/keae264.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/SI2\/SI180\/59038612\/keae264.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T03:54:46Z","timestamp":1725854086000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/SI2\/SI180\/7668451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":42,"journal-issue":{"issue":"SI2","published-online":{"date-parts":[[2024,5,10]]},"published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae264","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,5,10]]}}}